In recent years, several studies have examined the potential use of circulating galectin-1 as a potential biomarker in T2D and predictor of adverse events and explored its possible role in modulating kidney disease [43,47,48]. This evidence concerns the gene LGALS1 and type 2 diabetes mellitus.